heptad
repeat
hr
region
highli
conserv
motif
locat
glycoprotein
envelop
virus
form
sixhelix
bundl
structur
import
process
viru
fusion
peptid
deriv
hr
region
virus
also
shown
inhibit
viral
entri
porcin
epidem
diarrhea
viru
pedv
predict
hr
region
spike
glycoprotein
subunit
base
analysi
six
peptid
deriv
select
express
escherichia
coli
purifi
character
three
peptid
identifi
potenti
competit
inhibitor
pedv
vitro
infect
assay
peptid
repres
potent
inhibitor
studi
indic
immun
mice
elicit
antibodi
capabl
neutral
pedv
infect
vitro
result
demonstr
peptid
antibodi
serv
tool
dissect
fusion
mechan
pedv
guid
search
potent
inhibitor
therapeut
valu
pedv
infect
porcin
epidem
diarrhea
viru
pedv
famili
coronavirida
order
nidoviral
envelop
positivesens
singlestrand
rna
viru
readili
infect
pig
result
seriou
highli
contagi
swine
diseas
porcin
epidem
diarrhea
ped
character
sever
diarrhea
dehydr
suckl
piglet
lee
lin
et
al
puranaveja
et
al
wang
et
al
ped
first
identifi
europ
earli
viru
first
isol
belgium
pensaert
de
bouck
pedv
outbreak
sinc
report
mani
swineproduc
region
includ
china
chen
et
al
zhou
et
al
usa
canada
ojkic
et
al
europ
dastjerdi
et
al
mesquita
et
al
although
sow
herd
previous
vaccin
inactiv
vaccin
largescal
outbreak
ped
observ
suckl
piglet
mani
farm
china
start
late
result
increas
econom
loss
associ
high
morbid
mortal
basi
phylogenet
differ
fulllength
genom
sequenc
pedv
strain
classifi
two
distinct
genogroup
pedv
field
strain
isol
includ
deriv
vaccin
strain
belong
wherea
emerg
pedv
strain
isol
sinc
china
us
fell
ongo
import
diseas
necessit
develop
effect
vaccin
antivir
treatment
coronavirus
largest
genom
among
rna
virus
encod
sever
protein
embed
surfac
viral
envelop
gener
believ
spike
glycoprotein
initi
bind
cell
surfac
receptor
caus
conform
chang
expos
fusion
peptid
target
cell
membran
subsequ
highli
conserv
heptad
repeat
hr
region
interact
form
sixhelix
bundl
structur
contribut
fusion
viru
cell
membran
eckert
kim
glycoprotein
consist
subunit
locat
nterminu
bind
cell
receptor
ballestero
et
al
wherea
involv
viruscel
fusion
process
mani
vitro
studi
coronaviru
infect
report
exogen
solubl
peptid
bind
viral
therebi
effici
block
viral
entri
cell
inhibit
http
replic
bosch
et
al
deng
et
al
liu
et
al
liu
et
al
base
find
entri
inhibitor
also
identifi
coronavirus
virus
sever
acut
respiratori
syndrom
coronavirus
sarscov
yuan
et
al
middl
east
respiratori
syndrom
coronaviru
merscov
gao
et
al
lu
et
al
zhao
et
al
mous
hepat
viru
mhv
bosch
et
al
human
immunodefici
viru
hiv
imai
et
al
ebola
viru
watanab
et
al
typic
class
envelop
viru
pedv
presum
use
similar
membran
fusion
mechan
viral
entri
analysi
pedv
subunit
predict
presenc
two
hr
similar
envelop
virus
et
al
zheng
et
al
base
studi
fusion
mechan
coronavirus
describ
gener
approach
develop
success
use
studi
antivir
peptid
coronavirus
sarscov
mhv
merscov
similarli
studi
order
find
potent
inhibitor
viral
entri
seri
peptid
overlap
predict
hr
region
pedv
subunit
design
screen
inhibitori
effect
pedv
infect
assay
crossreact
peptid
pedv
also
investig
three
peptid
abl
inhibit
entri
identifi
potent
furthermor
immun
mice
elicit
antibodi
capabl
neutral
pedv
infect
vitro
vero
atcc
human
hepatocellular
carcinoma
cell
cultur
dulbecco
modifi
eagl
medium
dmem
gibco
supplement
fetal
bovin
serum
fb
gibco
penicillinstreptomycin
wv
humidifi
co
incub
use
two
pedv
strain
differ
genogroup
studi
viru
stock
recombin
pedv
strain
genbank
access
qin
et
al
express
green
fluoresc
protein
gfp
design
pedvgfp
studi
gener
transfect
vero
cell
pedv
infecti
cdna
clone
huang
yw
et
al
unpublish
data
follow
passag
vero
cell
pedv
strain
genbank
access
propag
vero
cell
briefli
vero
cell
seed
confluenc
plate
incub
overnight
wash
cell
pb
virus
moi
dilut
mainten
medium
trypsin
mmt
contain
dmem
tryptos
phosphat
broth
tpb
trypsin
sigma
cat
st
loui
mo
usa
penicillinstreptomycin
ad
well
h
incub
cell
wash
pb
cultur
mmt
cell
observ
daili
check
cytopath
effect
cpe
particularli
syncytium
format
cpe
obviou
whole
cell
cultur
supernat
cell
harvest
subject
three
freezethaw
cycl
prior
remov
cell
debri
centrifug
viru
titer
pedvgfp
determin
endpoint
dilut
tissu
cultur
infect
dose
tcid
vero
cell
respect
viru
stock
store
use
region
protein
pedv
strain
predict
use
comput
softwar
learncoilvmf
http
nightingalelcsmiteducgibinvmf
singh
et
al
hydropathi
plot
correspond
hr
motif
pedv
obtain
use
tmpred
program
expasi
swiss
institut
bioinformat
http
wwwchembnetorg
optim
solubl
express
protein
region
pedv
truncat
extend
silico
respect
design
six
peptid
basi
multipl
sequenc
align
differ
coronavirus
six
dna
fragment
correspond
desir
peptid
amplifi
polymeras
chain
reaction
pcr
fulllength
pedvgfp
construct
two
uniqu
restrict
site
bamhi
xhoi
introduc
upstream
primer
downstream
primer
dna
fragment
respect
amplicon
digest
bamhi
xhoi
ligat
appropri
digest
vector
contain
glutathion
stransferas
gst
tag
correspond
primer
pair
list
tabl
recombin
clone
transform
compet
e
coli
singl
coloni
inocul
luriabertani
lb
broth
contain
mgl
ampicillin
sigma
usa
incub
overnight
cultur
transfer
ml
fresh
lb
medium
largescal
protein
product
cultur
optic
densiti
od
reach
peptid
synthesi
induc
mm
iptg
sigma
usa
grown
anoth
h
cell
harvest
recombin
gstfuse
peptid
purifi
proteiniso
gst
resin
tansbionovo
beij
china
accord
manufactur
instruct
minor
modif
briefli
cell
harvest
centrifug
min
pellet
resuspend
ml
icecold
pb
ph
sonic
suspens
centrifug
min
supernat
filter
membran
bound
proteiniso
gst
resin
load
column
wash
column
volum
pb
gstfusion
peptid
elut
mm
reduc
glutathion
sigma
usa
elut
protein
dialyz
pb
adjust
desir
concentr
ultrafiltr
k
membran
millipor
purifi
solubl
gstfusion
peptid
analyz
sdspage
store
analysi
protein
concentr
measur
use
enhanc
bac
protein
assay
kit
beyotim
china
accord
manufactur
instruct
cytotox
peptid
cell
determin
use
mtt
cell
prolifer
cytotox
assay
kit
beyotim
china
tabl
sequenc
oligonucleotid
use
pcr
sequenc
restrict
endonucleas
site
bamhi
ital
xhoi
underlin
follow
manufactur
instruct
briefli
cell
seed
plate
densiti
well
maintain
co
h
cell
treat
peptid
h
mtt
solut
mgml
pb
ad
well
incub
h
formazan
solut
ad
mix
incub
h
optic
densiti
well
measur
nm
dosedepend
inhibitori
activ
determin
describ
previous
modif
chi
et
al
wang
et
al
cell
seed
confluenc
plate
infect
h
later
pedvgfp
moi
mix
recombin
hr
peptid
rang
concentr
h
uninfect
control
cultur
also
treat
solubl
peptid
dilut
mainten
media
mm
contain
dmem
tryptos
phosphat
broth
tpb
concentr
follow
treatment
viruspeptid
mixtur
remov
mm
ad
incub
h
point
number
gfp
posit
cell
cluster
count
quantifi
fluoresc
focusform
unit
ffu
inhibitori
concentr
ic
valu
calcul
accord
previous
describ
lu
et
al
result
express
averag
triplic
standard
deviat
analysi
varianc
anova
use
assess
inhibitori
percentag
pedv
infect
gst
fusion
peptid
comparison
gst
control
protein
differ
dose
statist
signific
set
pvalu
determin
effect
time
inhibitori
activ
three
differ
method
cell
monolay
treatment
peptid
dose
use
chi
et
al
lopper
compton
cell
pretreat
cell
incub
peptid
min
peptid
remov
cell
wash
pb
infect
pedvgfp
moi
h
cotreat
cell
incub
peptid
presenc
viral
inoculum
moi
h
posttreat
cell
infect
viru
moi
min
wash
pb
treat
peptid
h
case
cell
monolay
subsequ
incub
mm
fix
paraformaldehyd
assess
count
gfpposit
cell
cluster
result
express
averag
triplic
standard
deviat
experi
conduct
parallel
gst
fusion
peptid
gst
control
differ
treatment
pedv
peptid
clone
prokaryot
express
vector
contain
tag
recombin
protein
express
purifi
hisfus
purif
column
novoprotein
shanghai
china
describ
previous
huang
et
al
purifi
solubl
peptid
use
immunogen
mous
gener
polyclon
antibodi
mice
booster
immun
per
mous
administ
day
postvaccin
seven
day
final
booster
serum
collect
use
detect
mean
elisa
assay
purifi
solubl
pedv
dilut
buffer
mm
na
co
mm
nahco
ph
final
concentr
use
coat
well
plate
h
plate
wash
three
time
pb
tween
pbst
follow
block
bovin
serum
albumin
h
three
wash
pbst
plate
incub
polyclon
serial
dilut
h
three
wash
pbst
hrpconjug
goat
antimous
igg
antibodi
dilut
ad
h
three
wash
pbst
tmb
tetramethyl
benzidin
substrat
invitrogen
ca
usa
ad
incub
min
stop
addit
h
absorb
nm
quantifi
micropl
reader
infinit
pro
nanoqu
tecan
switzerland
sampletoneg
od
ratio
greater
consid
significantli
posit
chow
et
al
vn
assay
perform
monolay
cell
accord
previou
report
briefli
serial
dilut
preimmun
serum
antiserum
monoclon
antibodi
gift
dr
ying
fang
kansa
state
univers
mix
ffu
pedvgfp
mm
incub
h
form
virusantibodi
complex
ad
cell
grown
plate
dmem
contain
fb
h
incub
unabsorb
virus
thoroughli
remov
three
pb
wash
cell
fix
paraformaldehyd
h
postinfect
gfpposit
cell
count
ffu
immunofluoresc
microscopi
number
ffu
quantifi
normal
number
deriv
control
well
viru
mix
preimmun
sera
hr
region
pedv
strain
pedvgfp
glycoprotein
identifi
base
predict
learncoilvmf
program
fig
verifi
structuralbas
multipl
amino
acid
sequenc
align
two
pedv
strain
repres
pedvgfp
sever
coronavirus
human
coronaviru
hcov
transmiss
gastroenter
viru
tgev
merscov
sarscov
felin
infecti
periton
viru
fipv
porcin
deltacoronaviru
pdcov
avian
infecti
bronchiti
viru
ibv
porcin
respiratori
coronaviru
prcov
mhv
fig
subunit
pedv
like
sarscov
contain
two
hr
domain
region
residu
region
residu
fusion
peptid
fp
upstream
well
transmembran
domain
tm
cytoplasm
tail
ct
downstream
also
identifi
fig
similar
determin
hr
structur
sarscov
merscov
liu
et
al
lu
et
al
hypothes
fusion
pedv
cell
membran
subunit
pedv
chang
conform
form
fusion
core
insert
fp
target
cell
membran
howev
attempt
determin
crystal
structur
fusion
core
succeed
data
shown
empir
identifi
hr
region
screen
peptid
inhibitor
within
subunit
pedv
six
peptid
design
correspond
region
design
fig
express
gst
fusion
protein
e
coli
singl
gst
protein
express
express
vector
serv
control
product
solubl
subsequ
purifi
analyz
sdspage
respect
yield
band
expect
size
fig
express
level
product
vari
weak
amount
shown
addit
unknown
band
appear
peptid
like
attribut
distinct
hydrophob
featur
peptid
sinc
pedv
product
infect
cell
without
addit
p
zhao
et
al
antivir
research
trypsin
might
affect
integr
peptid
use
cell
vitro
model
instead
vero
cell
follow
viru
inhibitori
experi
confirm
peptid
toxic
effect
cell
monolay
expos
final
concentr
peptid
h
cell
viabil
analyz
use
mtt
assay
statist
signific
differ
viabil
control
untreat
cell
cell
expos
gstfusion
peptid
gst
protein
alon
supplement
fig
base
cell
viabil
result
peptid
concentr
chosen
test
dosedepend
pedv
infect
inhibit
cell
respect
first
test
effect
pedvpeptid
mixtur
stage
pedvgfp
inocul
cotreat
shown
fig
inhibitori
effect
pedvgfp
infect
comparison
gst
control
protein
wherea
statist
suppress
pedvgfp
infect
concentr
contrast
could
significantli
reduc
number
gfp
posit
cell
test
dose
except
maxim
reduct
respect
deduc
ic
valu
respect
inhibit
concentrationdepend
compar
untreat
group
tabl
peptid
potent
inhibitor
pedvgfp
viru
replic
among
test
result
indic
peptid
target
domain
pedv
subunit
inhibit
pedv
infect
specif
experi
conduct
identifi
step
entri
process
inhibit
three
peptid
concentr
concentr
show
signific
inhibit
gst
peptid
serv
control
three
differ
test
conduct
cell
expos
peptid
prior
infect
pretreat
entri
cotreat
viral
entri
posttreat
show
potent
antivir
activ
cotreat
lesser
extent
assay
fig
peptid
suppress
number
gfpposit
cell
posttreat
wherea
gst
control
inhibit
three
method
fig
result
indic
treatment
peptid
may
serv
antivir
intervent
suppress
pedv
entri
abil
peptid
crossreact
differ
pedv
strain
repres
strain
also
test
variou
peptid
region
pedvgfp
demonstr
antivir
activ
comparison
gst
control
reduc
number
pedvproduc
ffu
use
cotreat
determin
immunofluoresc
assay
ifa
antibodi
fig
b
hypothes
antibodi
may
also
block
viru
entri
peptid
therefor
immun
mice
solubl
pedv
protein
express
e
coli
test
reactiv
result
antisera
serum
antibodi
titer
rose
determin
elisa
use
antigen
moreov
antisera
could
recogn
either
protein
dilut
wherea
preimmun
sera
could
react
western
blot
analysi
data
shown
antisera
could
also
crossreact
solubl
protein
data
shown
result
suggest
fragment
immunogen
could
elicit
antibodi
specif
pedv
domain
determin
whether
immun
could
induc
neutral
antibodi
pedv
analyz
neutral
activ
antisera
vn
assay
use
pedvgfp
shown
fig
preimmun
serum
could
inhibit
pedvgfp
infect
previou
work
shown
monoclon
antibodi
mab
recogn
linear
epitop
gprlqpi
carboxytermin
subunit
exhibit
neutral
activ
pedv
cruz
et
al
similar
react
epitop
gift
dr
ying
fang
unpublish
data
use
posit
control
suppress
pedvgfp
infect
dilut
fig
antiserum
also
show
neutral
activ
could
inhibit
pedvgfp
infect
dilut
fig
data
demonstr
pedv
highli
immunogen
may
mimic
neutral
epitop
pedv
polyclon
antisera
abl
effici
block
pedv
infect
vitro
membran
fusion
fundament
import
infect
process
envelop
virus
control
one
viral
surfac
protein
must
undergo
conform
chang
harrison
use
hr
peptid
interfer
fusion
viral
envelop
host
membran
recogn
success
inhibit
infect
virus
class
fusion
protein
miller
et
al
porotto
et
al
earli
synthet
peptid
deriv
domain
discov
highli
potent
inhibitor
hiv
fusion
wild
et
al
peptid
brand
name
fuzeon
gener
name
enfuvirtid
licens
fda
alreadi
incorpor
clinic
regimen
strong
efficaci
pang
et
al
addit
hrderiv
peptid
merscov
sarscov
fcov
effect
inhibit
viral
membran
fusion
though
crystal
structur
pedv
protein
report
similar
region
identifi
amino
acid
sequenc
align
studi
peptid
correspond
pedv
express
order
empir
confirm
function
pedv
report
peptid
deriv
domain
particular
abl
inhibit
infect
felin
coronaviru
merscov
lu
et
al
sarscov
bosch
et
al
inhibitori
efficaci
relat
length
peptid
amino
acid
residu
essenti
inhibit
sarscov
infect
current
work
potenti
inhibitori
activ
peptid
studi
pedv
replic
vitro
antivir
crossreact
solubl
recombin
peptid
measur
three
differ
way
effici
suppress
pedv
replic
coand
posttreat
ic
less
howev
unknown
peptid
exert
impact
posttreat
hypothes
bind
peptid
surfac
infect
uninfect
cell
may
restrict
reinfect
spread
progeni
virus
also
pedv
inhibitori
effect
certain
degre
pretreat
might
come
presenc
peptid
bound
cellular
surfac
nonspecif
futur
studi
molecular
dissect
pedv
entri
warrant
answer
question
analysi
antigen
characterist
peptid
supplement
fig
indic
exhibit
strong
hydrophil
surfac
access
flexibl
line
characterist
immunogen
epitop
examin
inhibitori
effect
peptid
found
extra
ctermin
amino
acid
nrvet
compar
show
signific
inhibitori
activ
fig
differ
inhibit
effici
indic
conserv
cterminu
pedv
may
play
import
role
viral
invas
spike
glycoprotein
natur
found
trimer
structur
surfac
viru
particl
respons
adsorpt
fusion
induc
host
neutral
antibodi
immun
respons
highlight
import
vaccin
develop
polyclon
antibodi
induc
linear
antigen
studi
demonstr
strong
neutral
pedv
vitro
fig
probabl
due
blockag
viru
membran
fusion
basi
find
better
strategi
immun
may
devis
induc
neutral
antibodi
pedv
sequenc
summari
design
test
character
peptid
abl
inhibit
pedv
entri
infect
cell
cultur
peptid
exhibit
low
cytotox
biolog
function
vitro
prepar
antibodi
neutral
viru
capac
peptid
could
thu
serv
tool
dissect
fusion
mechan
pedv
well
potenti
antivir
drug
broad
applic
prevent
treatment
pedvassoci
diseas
fig
crossreact
pedvgfp
viru
strain
peptid
pedv
strain
repres
ifa
result
cell
fix
hpi
incub
monoclon
antibodi
protein
follow
incub
fitcconjug
goat
antimous
secondari
antibodi
b
comparison
peptid
inhibit
infect
quantif
ffu
base
ifa
result
gst
use
control
comparison
signific
p
signific
p
fig
vn
test
mice
antisera
cell
incub
indic
mixtur
pedv
ffuwel
dilut
antisera
reduct
ffu
measur
figur
repres
mean
valu
three
independ
experi
error
bar
indic
standard
deviat
